The Economic Times (India)
์ค๋ ์ฑํฅ
๊ธฐํ
๐ฎ๐ณ ์ธ๋ ยท "UBER" ยท ์ด 22๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
50.0
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 6,048๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 50.0(๊ท ํ)์ ๋๋ค. ๊ธ์ 0๊ฑด(0.0%)ยท์ค๋ฆฝ 6,048๊ฑด(100.0%)ยท๋ถ์ 0๊ฑด(0.0%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 0.0(์ค๋ ๊ท ํ)์ ๋๋ค.
The police claimed he published videos and posts against Ministers, including a woman member of the Cabinet headed by Chief Minister C. Joseph Vijay. The police said he also made remarks against ruling TVK functionaries
YouTuber Rachna Gurjar recently shared a video showing her house, jewellery, cash and lifestyle.
Sources said a case was registered against him by the Chennai City Cyber Crime Police for posting videos allegedly defaming the TVK-led coalition government in Tamil Nadu
BJP claims YouTuber Maridhas arrested for criticising TVK, seeks release
A village YouTuber from Shivpuri, Madhya Pradesh, was robbed of nearly Rs 8 lakh in cash and valuables, including jewellery and a crate of energy drinks, after burglars broke into her home. The intruders reportedly bolted her bedroom door from the outside while she and her husband slept.
A village YouTuber from Shivpuri, Madhya Pradesh, was robbed of nearly Rs 8 lakh in cash and valuables, including jewellery and a crate of energy drinks, after burglars broke into her home. The intruders reportedly bolted her bedroom door from the outside while she and her husband slept.
Despite the vast online audience, the physical gathering remained relatively limited, heavily populated by a major get-together of New Delhi-based YouTubers
Jyoti Malhotra, a resident of Hisar in Haryana, is accused of passing sensitive information to Pakistani intelligence officials.
YouTuber Jesse Ridgway and his wife Ashley shared a difficult personal update. They learned their unborn child had Down syndrome during pregnancy. This led to a deeply emotional decision. The couple is now focusing on recovery and supporting each other. They expressed gratitude for fan support during this challenging time. Ridgway detailed the medical considerations that influenced their choice.
Uber CEO Dara Khosrowshahi has cautioned against 'helicopter parenting,' arguing that over-protecting children hinders their long-term development. He believes facing and overcoming life's challenges is crucial for building character and finding satisfaction. While difficult for loving parents, this approach prepares kids for the real world, a sentiment echoed by Michael Dell.
Dalton Eatherly, known as ChudTheBuilder, remains jailed after a Tennessee judge refused to lower his $1 million bond. YouTuber Alex Rosen offered $100,000 toward the bond, but Judge William Goodman III kept existing restrictions. Eatherly also faces separate charges in Nashville. The main case stems from a May 13 courthouse shooting involving Joshua Fox in Clarksville.
Ritabrata Banerjee is a member of legislative assembly in West Bengal. He won from Uluberia Purba constituency on Trinamool Congressโ ticket.
Uber has implemented monthly usage caps of $1,500 per AI coding tool for its employees due to exceeding its AI budget. This move aims to responsibly manage the rising costs associated with AI adoption and experimentation across the company. The company previously reported that AI agents contributed to 10% of its code.
Goldman Sachs CEO David Solomon believes markets are in a "greed" mode, with ample liquidity to support a significant fundraising wave from major AI companies like OpenAI, Anthropic, and SpaceX. He suggests investors are optimistic and that this exuberance could continue, with markets potentially being early in the cycle for AI-driven growth.
A Hyderabad-based Uber recruiter's latest post has sparked discussion online after he shared an unusual hiring experience involving a candidate who allegedly disappeared on the day of joining after receiving a company-issued MacBook.
One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.
The programme, which is Indiaโs first State-wide and State-specific differentiated TB care initiative to reduce TB deaths, was launched in April 2022